Sign in
Taking people in United KingdomNo phase

Studying brain energy and glutamate levels in schizophrenia using brain scans

Compares brain chemistry and activity scans in people with schizophrenia and healthy volunteers.

Key facts

Who runs it
King's College London
Where
London, United KingdomSee the site
Trial code
Registry title
Energetics and Glutamate in Schizophrenia
Status
Recruiting
People taking part
75 people, planned
Started
4 Mar 2024
Expected to end
1 Dec 2028
Type of study
Observational, 3 groups
Treatments tested
  • MRI scan
  • PET-MR scan
Record updated
5 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy volunteers and adults with schizophrenia who take certain antipsychotic medicines. It compares brain chemistry and energy use using MRI and PET-MRI scans.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
Three groups: healthy volunteers with no psychiatric illness; people with schizophrenia (ICD-11 F20) in remission with no relapse in the past 6 months; people with treatment-resistant schizophrenia (PANSS total score above 70, SOFAS below 60).
Earlier treatment
People with schizophrenia must take one or more listed antipsychotics (olanzapine, risperidone, quetiapine, amisulpride, aripiprazole, paliperidone; clozapine for the treatment-resistant group) and take them as prescribed. Treatment-resistant group: at least two earlier antipsychotic trials of at least 6 weeks each.

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • Diabetes or past use of antidiabetic medicine
  • Cannot have a 7 Tesla MRI (for example metal or electronic implants) or has severe claustrophobia
  • Total radiation exposure of 10mSv or more within 12 months, including this study
  • Head injury with loss of consciousness for more than 5 minutes

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Healthy volunteer group:
  • No history of psychiatric illness, as assessed on the Mini neuropsychiatric Interview (MINI); Treatment responsive schizophrenia group:
  • Meeting ICD-11 criteria for schizophrenia (F20)
  • Meeting symptomatic consensus criteria for remission, defined as scores of mild or less on items P1, P2, P3, N1, N4, N6, G5 and G9 of the PANSS and no history of symptomatic relapse in the past 6 months
  • Currently receiving one or more of the following antipsychotic medications: Olanzapine; Risperidone; Quetiapine; Amisulpride; Aripiprazole; Paliperidone
  • Antipsychotic adherent, defined as having a score of >=moderate adherence on the Kemp scale; Treatment-resistant schizophrenia group:
  • Meeting ICD-11 criteria for schizophrenia (F20)
  • Meeting modified consensus criteria for treatment resistance, including history of at least two antipsychotic treatment trials each lasting ≥6 weeks at a dose of ≥400mg chlorpromazine equivalents
  • Total PANSS total score > 70
  • Moderate functional impairment (<60 on the SOFAS)
  • Currently receiving one or more of the following antipsychotic medications: Clozapine; Olanzapine; Risperidone; Quetiapine; Amisulpride; Aripiprazole; Paliperidone
  • Antipsychotic adherent, defined as having a score of >=moderate adherence on the Kemp scale

Who cannot take part

  • Severe claustrophobia prohibiting participation on PET or MRI 5. Body size above the comfortable limits for the MRI scanner. 6. Previous participation in research or clinical procedure/s involving ionising radiation, which, including the current study, would result in total radiation exposure >=10mSv within 12 months 7. History of head injury resulting in loss of consciousness for > 5 minutes 8. Meeting ICD-11 criteria for organic mental disorder (F00-F09) 9. Meeting ICD-11 criteria for mental and behavioural disorders due to psychoactive substance use (F10-F19) 10. With exclusion of nicotine or cannabis, meeting ICD-11 criteria for psychoactive substance dependence 11. Participation in clinical trial investigating any pharmacological agent other than a licensed antipsychotic compound in the last month
  • Diabetes or history of taking an antidiabetic medication 3. Presence of contraindication to MRI at 7 Tesla, including metallic or electronic implants and dental wires
  • All participants:
  • Pregnancy or breastfeeding
  • Lacking in mental capacity to provide informed consent to study participation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United Kingdom

  • South London and the Maudsley NHS Foundation TrustLondon, United KingdomContact: Alice Egerton, PhDTaking people

About the trial

What the trial wants to find out

The goal of this case-control study is to compare brain glutamate, glucose utilisation, lactate production and brain activity in healthy volunteers and people with a diagnosis of schizophrenia.

Read full original descriptionShow less

It investigates the following main questions:

Whether, compared to healthy volunteers, participants with schizophrenia show:

1. reduction in brain glucose utilisation 2. increased brain lactate 3. greater variability in brain glutamate

Participants will be asked to have a screening visit, a MRI brain scan and a PET-MRI brain scan.

The 3 groups in the trial

  • Healthy volunteers

    Treatment: MRI scan and PET-MR scan

  • Schizophrenia - remission

    Treatment: MRI scan and PET-MR scan

  • Treatment resistant schizophrenia

    Treatment: MRI scan and PET-MR scan

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Energetics and Glutamate in Schizophrenia
Plain-language title
Studying brain energy and glutamate levels in schizophrenia using brain scansGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06236048, who can take part
Record updated
5 September 2025